Characteristic | Data |
---|---|
Age (y) | |
Median | 59 |
Range | 49–73 |
Histology (n) | |
Invasive ductal carcinoma | 9 |
Invasive lobular carcinoma | 2 |
Receptor status (n) | |
ER+/PR+/HER2− | 6 |
ER+/PR−/HER2− | 5 |
Metastases at diagnosis (n) | |
Yes | 4 |
No | 7 |
Disease-free interval* (y) | |
Metastases at diagnosis (n = 4) | Not applicable |
No metastases at diagnosis (n = 7) | 7 (range, 3–19) |
Median lines of treatment before enrollment (n) | |
Adjuvant chemotherapy | |
Metastases at diagnosis (n = 4) | Not applicable |
No metastases at diagnosis (n = 7) | 1 (0–1) |
Adjuvant endocrine therapy | |
Metastases at diagnosis (n = 4) | Not applicable |
No metastases at diagnosis (n = 7) | 1 (0–2) |
Chemotherapy for metastatic disease | |
Metastases at diagnosis (n = 4) | 1 (0–1)† |
No metastases at diagnosis (n = 7) | 0 (0–1) |
Endocrine therapy for metastatic disease | |
Metastases at diagnosis (n = 4) | 2 (1–4) |
No metastases at diagnosis (n = 7) | 2 (1–6) |
CDK4/6 inhibitor | |
Metastases at diagnosis (n = 4) | 2 |
No metastases at diagnosis (n = 7) | 6 |
mTOR inhibitor | |
Metastases at diagnosis (n = 4) | 1 |
No metastases at diagnosis (n = 7) | 2 |
Dual PI3 kinase and mTOR inhibitor | |
Metastases at diagnosis (n = 4) | 0 |
No metastases at diagnosis (n = 7) | 1 |
Radiation therapy to metastatic disease | |
Metastases at diagnosis (n = 4) | 1 (bone) |
No metastases at diagnosis (n = 7) | 2 (bone) |
Median metastatic sites at enrollment (n) | 2 (range, 1–4) |
Location of metastatic sites at enrollment (n) | |
Bone | 8 (bone only, 5) |
Viscera (liver, vaginal cuff) | 4 |
Pleura | 5 |
Serosa/peritoneum | 2 |
Lymph node | 2 |
*Time from start of adjuvant therapy to first diagnosis of recurrence or metastatic disease.
↵†n = 1 with high-dose chemotherapy and stem cell transplantation.
PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; CDK = cyclin-dependent kinase; mTOR = mammalian target of rapamycin; PI3 = phosphoinositide 3.